Phase II pilot study of vemurafenib in patients with metastatic BRAF-mutated colorectal cancer Academic Article uri icon

Overview

MeSH Major

  • Carcinoma, Squamous Cell
  • Colorectal Neoplasms
  • Indoles
  • Mutation
  • Proto-Oncogene Proteins B-raf
  • Skin Neoplasms
  • Sulfonamides

abstract

  • In marked contrast to the results seen in patients with BRAF V600E-mutant melanoma, single-agent vemurafenib did not show meaningful clinical activity in patients with BRAF V600E mutant CRC. Combination strategies are now under development and may be informed by the presence of intratumor heterogeneity of KRAS and NRAS mutations.

publication date

  • December 2015

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC4669589

Digital Object Identifier (DOI)

  • 10.1200/JCO.2015.63.2497

PubMed ID

  • 26460303

Additional Document Info

start page

  • 4032

end page

  • 8

volume

  • 33

number

  • 34